Pricing Log in Create free account

Septerna, Inc. (SEPN) vs Zenas BioPharma, Inc. (ZBIO)

Septerna, Inc. and Zenas BioPharma, Inc. are both Biotechnology companies. Septerna, Inc. and Zenas BioPharma, Inc. are of similar size ($1.8B and $1.7B). Zenas BioPharma, Inc. has the higher net margin (0.00% vs −24.5%) and the higher return on invested capital (0.00% vs −189.0%). Across the 13 metrics below, Septerna, Inc. leads on 8 and Zenas BioPharma, Inc. on 5.

Valuation

Metric SEPN ZBIO Biotechnology median
P/E n/m n/m 8.50
P/S 16.42 n/m 9.71
P/B 4.20 6.30 2.13
Price to free cash flow 13.81 n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 12.66 n/m 9.21
Earnings yield (1.50%) (36.44%) (33.15%)
Free cash flow yield 7.24% (14.51%) (25.50%)

Profitability

Metric SEPN ZBIO Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (44.04%) 0.00% 0.00%
Net margin (24.51%) 0.00% 0.00%
Free cash flow margin 118.93% 0.00% 0.00%
Return on equity (6.34%) (199.04%) (56.36%)
Return on assets (4.94%) (97.39%) (48.04%)
Return on invested capital (189.01%) 0.00% 0.00%

Growth

Metric SEPN ZBIO Biotechnology median
Revenue growth (TTM) 13,520.11% — 6.02%
EPS growth (last fiscal year) 84.85% 29.04% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric SEPN ZBIO Biotechnology median
Debt to equity 0.00 1.57 0.00
Current ratio 4.99 9.93 4.72
Net debt to EBITDA 5.86 0.69 0.96

Dividend

Metric SEPN ZBIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SEPN ZBIO Biotechnology median
Market cap 1.75b 1.66b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack